Global Market Study on Microbiome Therapeutics

Jan 2018| PMR649A| Persistence Market Research

Report Highlights

This Persistence Market Research (PMR) report examines the global microbiome therapeutics market for the period 2018–2025. The primary objective of the report is to offer insights into market opportunity for microbiome therapeutics and pipeline developments in microbiome therapeutics market. The microbiome industry is at an early stage but is undergoing rapid developments in last five years. Particular microbiome therapeutics based on human intestinal microbiome are popular and numerous programs are being carried out to evaluate their therapeutic efficacy in treating or preventing gastrointestinal disorders such as C. difficile infection, ulcerative colitis, inflammatory bowel disease (IBD) etc. among others. The market for microbiome therapeutics is primarily driven by government initiatives in funding microbiome research, success of human microbiome project, need for reliable therapeutics for certain disease indications and huge pipeline of novel microbiome therapeutics.

A highly organized report for gaining maximum clarity

The report analyzes the global opportunity for microbiome based therapeutics in terms of value (US$ Mn) and forecast. The report begins with the market definition and explaining different disease indications for which microbiome therapeutics are being developed. The market view point section includes analysis of Persistence Market Research on key trends, drivers, restraints, and macro factors influencing global market. Opportunity analysis and recommendations section provided in the report allows to better equip clients with crystal clear decision making insights.

Section on venture capital provides the analysis of financing activities by venture partners in microbiome therapeutics in last 6-7 years. The section gives detailed description of venture financing along with the capital raised by various players in microbiome therapeutics market from 2011-2017. The section helps readers to gain insights into the source of financing for novel microbiome therapeutics, most of which are being developed by early stage of clinical stage biotechnology companies.

The next section of the report covers pipeline analysis of microbiome therapeutics. Pipeline analysis section provides analysis by development stage, disease indication, number of active clinical programs by therapeutic area, geographical distribution of clinical trials and analysis by product type. The section helps readers to identify potential competitors that are working on microbiome based drugs for the same therapeutic area. The section gives detailed description of over 120 clinical, preclinical and discovery programs.

The next section of the report highlights global microbiome therapeutics market potential by various indications including C. difficile infection, preterm birth & gynaecology conditions, type 2 diabetes and obesity. The section provides analysis on the bases of epidemiology and potential patient population for each of the indication mentioned and potential for microbiome therapeutics in the global market compared to currently available treatment drugs/products for each of the indication. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global microbiome therapeutics market.

Competitive landscape section is devoted to studying the competition in this novel market

In next section of the report on microbiome therapeutics market, a detailed competitive landscape is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Detailed company profiles include company-specific long-term and short-term strategies, pipeline products in microbiome therapeutics, recent developments, company’s microbiome activity analysis (in terms of pipeline, disease areas, industry sectors, number of licensing activities, partnerships, acquisitions and venture capital raised since 2010).

Market Taxonomy

By Indication

Type 2 Diabetes
Obesity
difficile infection
Primary Hyperoxyurea
By Region

U.S.
Europe
Japan
RoW

  • Table 1 : Activities in Microbiome Research Across the Globe (1/2)
  • Table 2 : Activities in Microbiome Research Across the Globe (2/2)
  • Table 3 : Global Microbiome Therapeutics Market Partnership and Collaborations (1/6)
  • Table 4 : Global Microbiome Therapeutics Market Partnership and Collaborations (2/6)
  • Table 5 : Global Microbiome Therapeutics Market Partnership and Collaborations (3/6)
  • Table 6 : Global Microbiome Therapeutics Market Partnership and Collaborations (4/6)
  • Table 7 : Global Microbiome Therapeutics Market Partnership and Collaborations (5/6)
  • Table 8 : Global Microbiome Therapeutics Market Partnership and Collaborations (6/6)
  • Table 9 : Venture Capital Investments in Microbiome Therapeutics (2017)
  • Table 10 : Venture Capital Investments in Microbiome Therapeutics (2016) (1/3)
  • Table 11 : Venture Capital Investments in Microbiome Therapeutics (2016) (2/3)
  • Table 12 : Venture Capital Investments in Microbiome Therapeutics (2016) (3/3)
  • Table 13 : Venture Capital Investments in Microbiome Therapeutics (2015) (2/3)
  • Table 14 : Venture Capital Investments in Microbiome Therapeutics (2014)
  • Table 15 : Venture Capital Investments in Microbiome Therapeutics (2013)
  • Table 16 : Venture Capital Investments in Microbiome Therapeutics (2011�2012)
  • Table 17 : Microbiome Therapeutics Pipeline Analysis (1/11)
  • Table 18 : Microbiome Therapeutics Pipeline Analysis (2/11)
  • Table 19 : Microbiome Therapeutics Pipeline Analysis (3/11)
  • Table 20 : Microbiome Therapeutics Pipeline Analysis (4/11)
  • Table 21 : Microbiome Therapeutics Pipeline Analysis (5/11)
  • Table 22 : Microbiome Therapeutics Pipeline Analysis (6/11)
  • Table 23 : Microbiome Therapeutics Pipeline Analysis (7/11)
  • Table 24 : Microbiome Therapeutics Pipeline Analysis (8/11)
  • Table 25 : Microbiome Therapeutics Pipeline Analysis (9/11)
  • Table 26 : Microbiome Therapeutics Pipeline Analysis (10/11)
  • Table 27 : Microbiome Therapeutics Pipeline Analysis (11/11)
  • Table 28 : Global Microbiome Therapeutics Market Opportunity Assessment, By Type 2 Diabetes Indication, 2018-2025
  • Table 29 : Global Microbiome Therapeutics Market Opportunity Assessment, C. difficile Infection, 2018-2025
  • Table 30 : Global Microbiome Therapeutics Market Opportunity Assessment, By ObesityIndication, 2018-2025
  • Table 31 : Global Microbiome Therapeutics Market Opportunity Assessment, By Obesity Indication, 2018-2025
  • Table 32 : Research Programs in the Field Microbiome in Preterm/Premature Birth (1/2)
  • Table 33 : Research Programs in the Field of Microbiome in Preterm/Premature Birth (2/2)
  • Table 34 : Seres Therapeutics Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 35 : Vedanta Biosciences Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 36 : Second Genome Therapeutics Microbiome Therapeutics Pipeline Analysis
  • Table 37 : Rebiotix, Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 38 : Synlogic, Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 39 : 4D Pharma PLC. Microbiome Therapeutics Pipeline Analysis
  • Table 40 : OxThera AB. Microbiome Therapeutics Pipeline Analysis
  • Table 41 : Immuron Ltd IMC. Microbiome Therapeutics Pipeline Analysis
  • Table 42 : Enterome Bioscience SA. Microbiome Therapeutics Pipeline Analysis
  • Table 43 : Evelo Biosciences Inc., Microbiome Therapeutics Pipeline Analysis
  • Table 44 : MicroBiome Therapeutics LLC., Microbiome Therapeutics Pipeline Analysis
  • Table 45 : LNC Therapeutics, SA. Microbiome Therapeutics Pipeline Analysis
  • Table 46 : Microbiome Therapeutics, LLC Pipeline Analysis
  • Table 47 : Microbiome Therapeutics, LLC Pipeline Analysis
  • Table 48 : Microbiome Therapeutics, LLC Pipeline Analysis
  • Table 49 : Osel Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 50 : Ritter Pharmaceuticals Inc. Microbiome Therapeutics Pipeline Analysis
  • Table 51 : AOBiome Microbiome Therapeutics Pipeline Analysis
  • Figure 1 : Global Microbiome Therapeutics Market Opportunity By Indication (2025)
  • Figure 2 : Number of Partnerships and Collaboration Deals in Microbiome Therapeutics Market (2010 � 2017)
  • Figure 3 : Partnerships and Collaborations Among Microbiome Industry
  • Figure 4 : Trends in Venture Capital Investments in Microbiome Therapeutics (2011 � 2017)
  • Figure 5 : Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, by Indication
  • Figure 6 : Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, By Phase
  • Figure 7 : Geographical Distribution of Clinical Trials for Microbiome
  • Figure 8 : Distribution of Microbiome Clinical Trials, By Drug Type
  • Figure 9 : Number Microbiome Therapeutics Drug Pipeline Projects By Indication (September 2017)
  • Figure 10 : Global Microbiome Therapeutics Market Value (US$ Mn) Opportunity Assessment 2018-2025
  • Figure 11 : Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity Assessment (2018�2025)
  • Figure 12 : Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 13 : Global C. difficile Infection Microbiome Therapeutics Market Opportunity Assessment (2018�2025)
  • Figure 14 : Global C. difficile Infection Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 15 : Global Obesity Microbiome Therapeutics Market Opportunity Assessment (2018�2025)
  • Figure 16 : Global Obesity Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 17 : Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity Assessment (2018�2025)
  • Figure 18 : Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity by Region (2025)
  • Figure 19 : Global CDI Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
  • Figure 20 : Incidence of C. difficile Infection Across Major Countries as Percentage of Total Hospital Admissions (2016)
  • Figure 21 : Composition of Microbiome of Reproductive Organs
  • Figure 22 : Number of People(Mn) with Diabetes, By Region (2015 & 2040)
  • Figure 23 : Global Diabetes Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
  • Figure 24 : Top Ten Countries/Territories For Diabetes Related Health Expenditure (2015)
  • Figure 25 : Global Obesity Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
  • Figure 26 : Number of people (Mn) with Obesity (2016 & 2020)
  • Figure 27 : Seres Therapeutics Inc. Microbiome Activity Analysis
  • Figure 28 : Vedanta Biosciences Microbiome Activity Analysis
  • Figure 29 : Second Genome Inc. Microbiome Activity Analysis
  • Figure 30 : Second Genome Therapeutics Pipeline Active and Inactive Programs By Indication
  • Figure 31 : Rebiotix Inc. Microbiome Activity Analysis
  • Figure 32 : Synlogic Inc. Microbiome Activity Analysis
  • Figure 33 : 4D pharma PLC. Microbiome Activity Analysis
  • Figure 34 : OxThera AB Microbiome Activity Analysis
  • Figure 35 : OxThera AB Pipeline Programs By Phase
  • Figure 36 : Immuron Ltd. Microbiome Activity Analysis
  • Figure 37 : Enterome Biosciences SA Microbiome Activity Analysis
  • Figure 38 : Evelo Biosciences Inc. Microbiome Activity Analysis
  • Figure 39 : Evelo Biosciences Inc. Pipeline Active and Inactive Programs By Indication
  • Figure 40 : Microbiome Therapeutics Inc. Activity Analysis
  • Figure 41 : Microbiome Therapeutics Inc. Pipeline, Active and Inactive Programs By Indication
  • Figure 42 : Ferring B.V. Microbiome Activity Analysis
  • Figure 43 : ViThera Pharmaceuticals, Inc. Microbiome Activity Analysis
  • Figure 44 : C3J Therapeutics, Inc. Microbiome Activity Analysis
  • Figure 45 : C3J Therapeutics Inc. Pipeline Active and Inactive Programs By Indication
  • Figure 46 : Second Genome Inc. Microbiome Activity Analysis
  • Figure 47 : Osel Pipeline Active and Inactive Programs By Indication
  • Figure 48 : Second Genome Inc. Microbiome Activity Analysis
  • Figure 49 : Second Genome Inc. Microbiome Activity Analysis
  • Figure 50 : AOBiome Clinical Pipeline Programs By Indication

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organization of all sizes.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report